The estimated Net Worth of Henry O Gosebruch is at least $16.9 Million dollars as of 16 May 2022. Mr. Gosebruch owns over 83,960 units of Aptinyx Inc stock worth over $6,136 and over the last 9 years he sold APTX stock worth over $16,645,906. In addition, he makes $215,378 as Independent Director at Aptinyx Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Gosebruch APTX stock SEC Form 4 insiders trading
Henry has made over 11 trades of the Aptinyx Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 83,960 units of APTX stock worth $4,606,046 on 16 May 2022.
The largest trade he's ever made was buying 100,000 units of Aptinyx Inc stock on 7 May 2019 worth over $386,000. On average, Henry trades about 9,256 units every 41 days since 2015. As of 16 May 2022 he still owns at least 100,583 units of Aptinyx Inc stock.
You can see the complete history of Mr. Gosebruch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Henry Gosebruch biography
Henry O. Gosebruch serves as Independent Director of the Company. Mr. Gosebruch has served as executive vice president and chief strategy officer at AbbVie, a global biopharmaceutical company. As a member of AbbVie's Executive Team, he is responsible for corporate strategy, business development and acquisitions, search and evaluation, alliance management, early-stage collaborations, and the company's corporate strategic venture capital arm, AbbVie Ventures. Prior to joining AbbVie, Mr. Gosebruch spent more than 20 years as a member of J.P. Morgan's North American M&A Group, most recently as its co-head. Mr. Gosebruch currently serves as a member of the Advisory Board for the Life Sciences & Management Program at the University of Pennsylvania. Mr. Gosebruch graduated from the Wharton School at the University of Pennsylvania.
What is the salary of Henry Gosebruch?
As the Independent Director of Aptinyx Inc, the total compensation of Henry Gosebruch at Aptinyx Inc is $215,378. There are 6 executives at Aptinyx Inc getting paid more, with Norbert Riedel having the highest compensation of $5,635,420.
How old is Henry Gosebruch?
Henry Gosebruch is 47, he's been the Independent Director of Aptinyx Inc since 2019. There are 7 older and 4 younger executives at Aptinyx Inc. The oldest executive at Aptinyx Inc is Elisha Gould, 63, who is the Independent Director.
What's Henry Gosebruch's mailing address?
Henry's mailing address filed with the SEC is C/O APTINYX INC., 909 DAVIS ST, SUITE 600, EVANSTON, IL, 60201.
Insiders trading at Aptinyx Inc
Over the last 6 years, insiders at Aptinyx Inc have traded over $0 worth of Aptinyx Inc stock and bought 10,337,357 units worth $55,328,087 . The most active insiders traders include Street Partners Llc Adams, Patrick G Enright, and James N Topper. On average, Aptinyx Inc executives and independent directors trade stock every 35 days with the average trade being worth of $18,161. The most recent stock trade was executed by Joan W. Miller on 13 January 2022, trading 17,700 units of APTX stock currently worth $50,091.
What does Aptinyx Inc do?
welcome to our company page and thank you for your interest in aptinyx inc. aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the nmda receptor to enhance pathways involved with nerve cell communication. our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. at aptinyx, we remain committed and responsive to our employees. we offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. if you are interested in learning more, please visit our website at www.aptinyx.com.
What does Aptinyx Inc's logo look like?
Complete history of Mr. Gosebruch stock trades at Abbvie Inc and Aptinyx Inc
Aptinyx Inc executives and stock owners
Aptinyx Inc executives and other stock owners filed with the SEC include:
-
Norbert Riedel,
President, Chief Executive Officer, Director -
Ashish Khanna,
Chief Financial Officer, Chief Business Officer -
Andrew Kidd,
Chief Operating Officer -
Dr. Norbert G. Riedel,
Exec. Chairman -
Dr. Andrew D. Kidd B.M. B.Ch., M.D.,
CEO, Pres & Director -
Ashish Khanna,
CFO & Chief Bus. Officer -
Henry Gosebruch,
Independent Director -
Rachel Sherman,
Independent Director -
Robert Hombach,
Independent Director -
Patrick Enright,
Independent Chairman of the Board -
Adam Koppel,
Independent Director -
Elisha Gould,
Independent Director -
Tim Noffke,
VP of Program Management & Chief of Staff -
Dr. Harald Murck M.D., Ph.D.,
VP of Clinical & Medical Affairs -
Patrick Flavin,
Sr. Mang. of Corp. Devel. & Investor Relations -
Dr. Kathryn King Ph.D.,
Sr. VP of Clinical & CMC Operations -
Molly Dir,
VP of HR -
Juan Estupinan,
VP of Fin. & Accounting and Controller -
Capital Life Sciences Inves...,
-
Gilmore Neil O'neill,
-
Terry P Gould,
-
Leaf Venture Management Iii...,
-
David Houck,
Chief Development Officer -
Torsten M. Madsen,
Chief Medical Officer -
James N Topper,
Director -
Life Sciences Viii, L.P.Fhm...,
-
Capital Partners Ii, Llc Ta...,
-
Wilbur H Gantz,
Director -
Joseph R. Moskal,
Chief Scientific Officer -
Street Partners Llc Adams,
10% owner -
Liam Ratcliffe,
Director -
Joan W. Miller,